BCIM
TEVA icon

British Columbia Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

British Columbia Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,102
Closed -$222K – 721
2025
Q4 		$222K Buy
+7,102
New +$175K ﹤0.01% 694
2023
Q4 		– Sell
-11,302
Closed -$115K – 807
2023
Q3 		$115K Hold
11,302
– – ﹤0.01% 802
2023
Q2 		$85.1K Sell
11,302
-17,400
-61% -$141K ﹤0.01% 801
2023
Q1 		$254K Sell
28,702
-14,200
-33% -$140K ﹤0.01% 799
2022
Q4 		$391K Sell
42,902
-1,900
-4% -$16.6K ﹤0.01% 783
2022
Q3 		$362K Buy
44,802
+5,300
+13% +$46.9K ﹤0.01% 788
2022
Q2 		$297K Buy
39,502
+180
+0.5% +$1.57K ﹤0.01% 800
2022
Q1 		$369K Buy
39,322
+5,500
+16% +$45.9K ﹤0.01% 828
2021
Q4 		$271K Hold
33,822
– – ﹤0.01% 834
2021
Q3 		$329K Hold
33,822
– – ﹤0.01% 833
2021
Q2 		$335K Sell
33,822
-2,300
-6% -$24.3K ﹤0.01% 837
2021
Q1 		$417K Sell
36,122
-3,000
-8% -$34.4K ﹤0.01% 821
2020
Q4 		$378K Sell
39,122
-9,600
-20% -$92K ﹤0.01% 814
2020
Q3 		$439K Sell
48,722
-7,500
-13% -$79.3K ﹤0.01% 800
2020
Q2 		$693K Sell
56,222
-23,000
-29% -$260K 0.01% 775
2020
Q1 		$711K Sell
79,222
-56,300
-42% -$577K 0.01% 644
2019
Q4 		$1.33M Buy
135,522
+18,200
+16% +$162K 0.01% 755
2019
Q3 		$807K Sell
117,322
-37,300
-24% -$286K 0.01% 734
2019
Q2 		$1.43M Sell
154,622
-8,400
-5% -$101K 0.01% 732
2019
Q1 		$2.56M Buy
163,022
+12,100
+8% +$213K 0.02% 609
2018
Q4 		$2.33M Sell
150,922
-30,900
-17% -$633K 0.02% 639
2018
Q3 		$3.92M Sell
181,822
-32,400
-15% -$752K 0.04% 453
2018
Q2 		$5.21M Sell
214,222
-74,883
-26% -$1.53M 0.05% 440
2018
Q1 		$4.94M Buy
289,105
+62,000
+27% +$1.21M 0.04% 502
2017
Q4 		$4.3M Sell
227,105
-24,800
-10% -$373K 0.03% 533
2017
Q3 		$4.43M Buy
251,905
+140,000
+125% +$3.15M 0.03% 497
2017
Q2 		$3.72M Hold
111,905
– – 0.03% 538
2017
Q1 		$3.59M Buy
111,905
+8,400
+8% +$287K 0.03% 548
2016
Q4 		$3.75M Buy
103,505
+76,705
+286% +$3.06M 0.03% 536
2016
Q3 		$1.23M Hold
26,800
– – 0.01% 639
2016
Q2 		$1.35M Buy
26,800
+4,100
+18% +$218K 0.01% 631
2016
Q1 		$1.22M Buy
22,700
+3,200
+16% +$188K 0.01% 639
2015
Q4 		$1.28M Hold
19,500
– – 0.01% 653
2015
Q3 		$1.1M Buy
19,500
+3,000
+18% +$195K 0.01% 629
2015
Q2 		$975K Sell
16,500
-1,000
-6% -$61.7K 0.01% 675
2015
Q1 		$1.09M Hold
17,500
– – 0.01% 641
2014
Q4 		$1.01M Buy
17,500
+1,500
+9% +$83.6K 0.01% 632
2014
Q3 		$860K Hold
16,000
– – 0.01% 627
2014
Q2 		$839K Sell
16,000
-2,476
-13% -$127K 0.01% 637
2014
Q1 		$976K Hold
18,476
– – 0.01% 617
2013
Q4 		$741K Sell
18,476
-22,197
-55% -$874K 0.01% 642
2013
Q3 		$1.54M Sell
40,673
-20,672
-34% -$806K 0.01% 584
2013
Q2 		$2.4M Buy
+61,345
New +$2.39M 0.02% 521

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

British Columbia Investment Management's TEVA Position: Q1 2026 in Review

British Columbia Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 7,102 shares — an estimated $222K sold.

British Columbia Investment Management first reported a position in TEVA in Q2 2013 and held it in 43 quarters. The position peaked at $5.21M in Q2 2018. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • British Columbia Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • British Columbia Investment Management sold 7,102 Teva Pharmaceuticals shares in Q1 2026, an estimated $222K.
  • British Columbia Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • British Columbia Investment Management's Teva Pharmaceuticals position peaked at $5.21M in Q2 2018.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on British Columbia Investment Management's 13F filing for Q1 2026, filed 14 May 2026.